PROLOR Biotech Initiates Phase II Clinical Trial of its Longer-Acting Version of Human Growth Hormone  ∼ PROLOR is developing hGH-CTP that requires only bi-monthly injections, rather than the multiple weekly injections required by current hGH therapy. Phase II clinical trial follows a successful Phase I clinical trial, which suggested, in addition to meeting all safety and tolerability endpoints, that hGH-CTP could potentially be effective when injected just twice per month. Read More